Cormorant Asset Management, LP Amarin Corp Plcuk Transaction History

Cormorant Asset Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$4.04 - $5.31 $1.21 Million - $1.59 Million	-300,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.64 - $7.76 $1.09 Million - $2.33 Million	-300,000 Reduced 50.0%	300,000 $1.26 Million
Q2 2020 Aug 14, 2020	SELL	$4.78 - $8.26 $1.43 Million - $2.48 Million	-300,000 Reduced 33.33%	600,000 $4.15 Million
Q1 2020 May 15, 2020	SELL	$4.0 - $21.53 $1.6 Million - $8.61 Million	-400,000 Reduced 30.77%	900,000 $3.6 Million
Q4 2019 Feb 14, 2020	SELL	$13.94 - $24.12 $446,080 - $771,840	-32,000 Reduced 2.4%	1,300,000 $27.9 Million
Q3 2019 Nov 14, 2019	BUY	$13.89 - $23.16 $11.6 Million - $19.3 Million	832,000 Added 166.4%	1,332,000 $20.2 Million
Q2 2019 Aug 14, 2019	SELL	$16.27 - $20.51 $1.63 Million - $2.05 Million	-100,000 Reduced 16.67%	500,000 $9.7 Million
Q1 2019 May 15, 2019	SELL	$12.61 - $22.33 $1.26 Million - $2.23 Million	-100,000 Reduced 14.29%	600,000 $12.5 Million
Q4 2018 Feb 14, 2019	BUY	$12.41 - $22.98 $2.48 Million - $4.6 Million	200,000 Added 40.0%	700,000 $9.53 Million
Q3 2018 Nov 14, 2018	BUY	$2.45 - $16.27 $1.23 Million - $8.14 Million	500,000 New	500,000 $8.14 Million

176

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $222M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.